These results supported our assumption that in HR+ breast cancers, high MITH indicated CDK4/6 inhibitor resistance and CDK2/4/6 inhibitor may be an effective therapeutic option for the high-MITH HR+ breast cancers. Here, CDK4 is linked to breast cancer.